Genelux
Genelux's revenue was flat at $0 million in fiscal 2025. Its operating margin was −415,175.0%, down from −396,200.0% a year earlier. Free cash flow was −$26 million. The diluted share count rose 18.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Genelux does
Genelux is a drug developer in Westlake Village, California, working on cancer treatments made from viruses. Its drug candidates are modified strains of the vaccinia virus, meant to infect and kill tumor cells and prompt the patient's immune system to attack the tumor. It has no approved products and has never had revenue from product sales.
Its lead candidate, Olvi-Vec, is in three trials: a final-stage (Phase 3) U.S. trial in ovarian cancer that no longer responds to platinum chemotherapy, a Phase 2 U.S. trial in a common type of lung cancer (non-small cell), and an early-to-mid-stage trial in China in small cell lung cancer. A key aim is to show that Olvi-Vec can make tumors respond to platinum chemotherapy again. Genelux has licensed the rights to Olvi-Vec in mainland China, Taiwan, Hong Kong and Macau to a partner, Newsoara, and plans to keep U.S. rights and build its own sales team there. It also has a library of hundreds of other virus versions for future candidates.
Genelux makes its own trial supplies at a plant in San Diego. It lost $32.1 million in 2025.
Its biggest risks, as it describes them
- Continued losses and the need to raise more money; its auditor has raised substantial doubt about its ability to keep going.
- Its future rests largely on Olvi-Vec, its only drug candidate in clinical trials, which may fail or not be approved.
- Delays or setbacks in its trials, including the Phase 3 ovarian cancer trial.
- Competition from many other cancer treatments, including other virus-based therapies and antibody drugs.
- Problems making its products at its own plant, or building a business to sell them if approved.
Income statement
Genelux lost money in fiscal 2025: a net loss of $32 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 0 | 23 | 31 | — |
| Debt incl. finance leases | 8 | — | — | — |
| Net debt (negative means net cash) | 8 | — | — | — |
| Net debt to EBITDA | — | — | — | — |
| Debt to equity | — | — | — | — |
| Interest coverage | −11.4x | −139.7x | — | — |
| Current ratio | 0.1x | 3.7x | 4.6x | 2.4x |
| Quick ratio | 0.1x | 3.7x | 4.6x | 2.4x |
Cash flow
Projections
Project Genelux's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Genelux shares on the open market, and 6 insiders sold $327,695, $108,800 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Thomas ZindrickPresident and CEO | Sold | 34,463 | $2.67 | $92,016 | Form 4 |
| Aug 31, 2026 | Joseph CappelloChief Technical Officer | Sold | 10,257 | $2.74 | $28,104 | Form 4 |
| Aug 31, 2026 | Yong YuChief Scientific Officer | Sold | 9,683 | $2.75 | $26,628 | Form 4 |
| Aug 4, 2026 | Thomas ZindrickPresident and CEO | Sold | 3,023 | $2.95 | $8,918 | Form 4 |
| Aug 4, 2026 | Joseph CappelloChief Technical Officer | Sold | 653 | $2.95 | $1,926 | Form 4 |
| Aug 4, 2026 | Yong YuChief Scientific Officer | Sold | 653 | $2.94 | $1,920 | Form 4 |
| Jul 1, 2026 | John W SmitherDirector | Sold | 12,000 | $2.91 | $34,920 | Form 4 |
| Jun 3, 2026 | Ralph SmallingHead of Regulatory | Sold | 192 | $2.93 | $563 | Form 4 |
| Jun 1, 2026 | John ThomasDirector | Sold plan | 10,000 | $2.98 | $29,800 | Form 4 |
| May 11, 2026 | Thomas ZindrickPresident and CEO | Sold | 2,798 | $2.94 | $8,226 | Form 4 |
| May 11, 2026 | Yong YuChief Scientific Officer | Sold | 605 | $2.97 | $1,797 | Form 4 |
| May 11, 2026 | Ralph SmallingHead of Regulatory | Sold | 270 | $2.98 | $805 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −12,627.9% | −270,207.8% | −329,575.0% |
| Altman Z'' | −25.13 | −21.82 | −55.62 |
| Accruals ratio | −48.0% | −27.6% | −25.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Fail | Fail |
| F-score | — | — | — |
Compare
Put Genelux side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Genelux | FY25 | 0.0% | −415,175.0% | −329,575.0% | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 11 | 0 | 0 | 0 |
| Revenue growth | — | −98.5% | −95.3% | 0.0% |
| Gross profit | — | — | — | — |
| Research and development | 9 | 13 | 19 | 20 |
| Operating income | −3 | −24 | −32 | −33 |
| Net income | −5 | −28 | −30 | −32 |
| Diluted EPS (US$) | −0.57 | −1.16 | −0.95 | −0.86 |
| Diluted shares (millions) | 9 | 24 | 32 | 37 |
| Cash flow | ||||
| Cash from operations | −4 | −20 | −21 | −25 |
| Capital expenditure | 0 | 1 | 0 | 1 |
| Free cash flow | −4 | −21 | −22 | −26 |
| Dividends paid | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 6 | 6 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 0 | 23 | 31 | — |
| Debt incl. finance leases | 8 | — | — | — |
| Total assets | 6 | 28 | 35 | 19 |
| Total liabilities | 41 | 8 | 8 | 8 |
| Shareholders' equity | −36 | 20 | 26 | 12 |
| Margins and ratios | ||||
| Gross margin | — | — | — | — |
| Operating margin | −27.2% | −14,214.7% | −396,200.0% | −415,175.0% |
| Net margin | −47.0% | −16,645.3% | −373,362.5% | −401,812.5% |
| Free cash flow margin | −32.7% | −12,529.4% | −270,112.5% | −329,575.0% |
| Rule of 40 (growth + FCF margin) | — | −12,627.9% | −270,207.8% | −329,575.0% |
| Return on capital | — | — | — | — |
| Return on equity | — | — | −130.6% | −170.0% |
| Return on assets | — | −169.3% | −95.4% | −119.6% |
| Net debt to EBITDA | — | — | — | — |